Changes in Hong Kong stocks | Xintai Healthcare (02291) fell nearly 15% in early trading, net profit fell by nearly 20% year-on-year in the first half of the year, followed up or was excluded from Hong Kong Stock Connect

The Zhitong Finance App learned that Xintai Healthcare (02291) fell nearly 15% in early trading. As of press release, it was down 13.9% to HK$12.64, with a turnover of HK$2.551 million.

According to the news, Xintai Medical announced interim results. Revenue for the first half of the year was 310 million yuan, a year-on-year decrease of 5.94%; net profit to mother was 147 million yuan, a decrease of 19.49% year-on-year. In addition, Xintai Medical issued an announcement to acquire 54.2384% of Minwei Biotech's shares from the controlling shareholder, Lepu Biotech, at a cash cost of RMB 1,088 billion, to enter the high-growth metabolic and cardiovascular circuit and improve the strategic layout of full-cycle disease treatment.

Notably, Hang Seng Index announced the quarterly review results. Changes to the Hang Seng Composite Index will be implemented after the market closes on September 4 (Friday) and will take effect on September 7 (Monday). Among them, Xintai Healthcare was excluded from the Hang Seng Composite Index, and may later be removed from Hong Kong Stock Connect because it did not meet the requirements of the Hang Seng Composite Index.